2Ono S,Ichikura T,Mochizuki H.The pathogenesis of the systemic inflammatory response syndrome and compensatory antiinflammatory response syndrome following surgical stress[J].Nippon Geka Gakkai Zasshi,2003,104:499-505.
3Levels J H,Lemaire L C,van den Ende A E,et al.Lipid compo-sition and lipopolysaccharide binding capacity of lipoproteins in plasma and lymph of patients with systemic inflammatory response syndrome and multiple organ failure[J].Crit Care Med,2003,31:1647-1653.
4Matsukawa H,Hara A,Ito T,et al.Continuous arterial infusion of protease inhibitor with supplementory therapy for the patients with severe acute pancreatitis-clinical effect of arterial injection of ulinastatin[J].Nippon Shokakibyo Gakkai Zasshi,1998,95:1229-1234.
5Bone R C,Balk R A,Cerra F B,et al.The ACCP/SCCM consensus conference on sepsis and organ failure[J].Chest,1992,101:1644-1655.
6Masuda T,Sato K,Noda C,et al.Protective effect of urinary trypsin inhibitor on myocardial mitochondria during hemorrhagic shock and reperfusion[J].Crit Care Med,2003,31:1987-1992.
7Okamotoll.Use of Ulinastatin for improving the viability of liver grafts Transplantation Proc, 1993,25∶2961
